Company: PSTV
Filing Date: 2025-04-01
Form Type: PRER14A
Source: 0001140361-25-011649
Chunk: 23

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-01
Form: PRER14A
Chunk 23
---
the “Floor Price”), subject to appropriate adjustment for any stock dividend, stock split, stock combination, reclassification or similar transaction, and the related number of shares of Common Stock issuable upon exercise may be correspondingly increased. In the event that the exercise price of the Series A Warrants and Series B Warrants is reduced to the Floor Price pursuant to the reset provision, the 28,042,140 outstanding Series A Warrants would become exercisable for an aggregate of up to 280,421,380 shares of Common Stock at the Floor Price and the 28,042,140 outstanding Series B Warrants would become exercisable for an aggregate of up to 420,632,070 shares of Common Stock, or an aggregate of up to 1,261,896,210 shares of Common Stock assuming the Series B Warrants are exercised pursuant to the “zero exercise price” provision set forth in Series B Warrant, which is referred to in the Series B Warrant as an “alternative cashless exercise.” For more information regarding the reset provision, see “—Reset Provision” below. The Series A Warrants are exercisable only following stockholder approval and expire five (5) years thereafter. The number of securities issuable under the Series A Warrant is subject to adjustment as described in more detail in the Series A Warrant. The Series A Warrants are also subject to anti-dilution protection upon any subsequent transaction at a fixed price lower than the warrant exercise price then in effect, as more fully described in the Series A Warrants. The Series B Warrants are exercisable only following stockholder approval and expire two and one-half (2.5) years thereafter. The Series B Warrants are exercisable for cash or pursuant to a zero exercise price provision, pursuant to which the Series B Warrants can be exercised without further payment to the Company and for three times the number of shares of Common Stock issuable upon exercise of the Series B Warrants for cash. The terms of the Warrants require that the Company seek such approval as may be required by the rules and regulations of Nasdaq (the “Warrant Stockholder Approval”). Accordingly, pursuant to this proposal we are seeking stockholder approval of the Warrants and the shares of Common Stock issuable thereunder, including without limitation:

| • | to render inapplicable clause (i) of the definition of the Floor Price contained in Section 1.11 of the Series A Warrants and Section 1.10 of the Series B Warrants;